Infection: Tracking your few aftercare instructions or not following up can raise the possibility of infection in the treated areas
A healthcare provider should be contacted if side effects like chest pain, pounding or rapid heartbeat, difficulty urinating, long-lasting insomnia or shortness of breath occur
Retatrutide targets appetite and energy pathways, while MOTS-c supports mitochondrial function and glucose metabolism
For obesity treatment, dose escalation protocols starting at lower doses (e.g., 2 mg) and gradually increasing to maintenance doses (e.g., 4 mg, 8 mg, or 12 mg) have been studied Link below for more detailed information: Product Overview: Retatru/Cagrilintide is a dual-compound research peptide combining Retatru, a novel multi-agonist peptide with activity across GLP-1, GIP, and glucagon pathways, and Cagrilintide, an amylin analog